Epidemiologic features and burden of atopic dermatitis in adolescent and adult patients: A cross-sectional multicenter study

Gloria Sanclemente, MD, MSc, PhD*, Natalia Hernandez, MD, MScb, Daniela Chaparro, MD, MSCc, Liliana Tamayo, MDd and Angela Lopez, MDe, Colombian Atopic Dermatitis Research Group†

ABSTRACT

Background: Atopic dermatitis (AD) is considered as one of the most frequent chronic skin conditions. Previous AD epidemiologic studies have been mainly retrospective and/or have been performed through surveys instead of in-person visits. Epidemiological studies concerning AD in Latin American countries are scarce.

Objective: To describe sociodemographic and clinical features and the economic burden of AD on children and adult patients in Colombia through in-person visits.

Methods: This was a cross-sectional study of 212 patients that included sociodemographic and clinimetric data. The diagnostic criteria of Hanifin and Rajka was used and data relating to disease distribution, disease severity (through the BSA: Body surface area; EASI: Eczema Area and Severity Index; SCORAD: Scoring Atopic Dermatitis), Fitzpatrick’s skin phototypes, personal and familiar history of allergic diseases, previous treatments, and personal history of comorbidities, was collected.

Results: Patient age range was 12–76, and 52.8% were female. Disease distribution was mainly flexural (19.6%). Early age start, Denni-Morgan fold, and infections tendency were more frequent in adolescents compared to adults. Mean age of diagnosis was 12 years old, AD diagnosis was made mostly by a dermatologist, 48.1% (102 patients) reported alcohol consumption, and 59% of consumers were heavy drinkers. Comorbidities found were: chronic rhinitis (68.9%) food allergy (32.5%), allergic conjunctivitis (29.7%), and asthma (28.8%). Around 81% earned less than $896 US dollars and 59% invested 6–30% of their monthly budget yearly, and 40% had work or school absenteeism. Mean scores of BSA, EASI, and SCORAD involvement were 32.6, 13.7, and 42.4, respectively.

*Group of Investigative Dermatology (GRID), University of Antioquia, Medellín, Colombia
†Corresponding author. Group of Investigative Dermatology (GRID), School of Medicine, University of Antioquia Medellín, Carrera 25 A # 1 A Sur 45, Of 1247, Torre Médica 2, El Tesoro, Medellín, Colombia. E-mails: sanclementegloria@gmail.com; gloria.sanclemente@udea.edu.co
† Colombian Atopic Dermatitis Research Group Members: Natalia Hernandez (Dermatosoluciones SAS); Gloria Sanclemente (Group of Investigative Dermatology (GRID), University of Antioquia, Medellín, Colombia); Daniela Chaparro (Pontificia Universidad Javeriana, Bogotá, Colombia); Ángela López (IPS Fototerapia Bojanini y López SAS); Andrés Cortes; Ángela Seidel; Clara Inés Ortiz; Claudia Arenas (Centro Dermatológico Federico Urraza Acosta, Bogotá, Colombia); Esperanza Meléndez (Hospital Universidad del Norte, Barranquilla, Colombia); Julio Amador (Universidad Militar, Bogotá, Colombia); Liliana Tamayo (Universidad Pontificia Bolivariana, Medellín, Colombia); Lina Colmenares (Universidad CES, Medellín, Colombia); María Claudia Guzmán; María Claudia Torres; Mariela Tavera; Mauricio Torres (Fundación Ciencias de la Salud, Bogotá, Colombia); Miriam Vargas (Universidad del valle, Cali, Colombia); Mónica Novoa (Fundación Ciencias de la Salud, Bogotá, Colombia); Mónica Rivera; Natalia Vélez (Universidad CES, Medellín), Oscar Mora (Fundación Ciencias de la Salud, Bogotá, Colombia); Paola Cárdenas (Universidad CES, Medellín), Oscar Medina; Paola Cárdenas
Full list of author information is available at the end of the article
http://doi.org/10.1016/j.waojou.2021.100611
Received 26 June 2021; Received in revised from 25 October 2021; Accepted 2 November 2021
Online publication date xxx

1939-4551/© 2021 The Author(s). Published by Elsevier Inc. on behalf of World Allergy Organization. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Conclusions: This study adds well-supported data through an in-depth clinical and economical characterization of Colombian adolescents and adult patients with atopic dermatitis and shows its high impact and burden on patients and their families. It also contributes to understand the burden of AD in Latin America.

Keywords: Atopic dermatitis, Burden, Epidemiology, Cross-sectional, Comorbidities, Direct costs

INTRODUCTION

Atopic dermatitis (AD) is an inflammatory and chronic skin disease, frequently associated with other atopic manifestations that can affect both children and adults. Worldwide prevalence of the disease calculated through the use of mailed questionnaires and not by in-person evaluations ranges from 0.2% in China at ages of 13–14 years through 24.6% in Colombia.\(^1\) It is considered one of the most frequent chronic skin conditions and several studies have documented a high burden of the disease, with an important impact on public health.\(^2\)

The burden of AD has been well characterized, especially in the pediatric populations in developed countries;\(^3,4\) being associated with sleep disturbances, impact on social functioning, and choice of occupation, resulting in impaired quality of life (QoL).\(^5\) Similarly, among adult patients with AD, the burden includes not only its awkward skin symptoms,\(^6\) but also impaired mental health, and reductions in work productivity.\(^7\) In fact, this burden is higher in the severe presentation of the disease, which has been reported in 10%-34% of adult patients.\(^8\)

It has been described that AD prevalence has been increasing over the last 4 decades in several developed European countries due to lifestyle and environmental factors,\(^9\) but it has also been increasing in developing countries of Asia, Africa, Latin America, and the Middle East;\(^10\) more likely because of increasing urbanization, pollution, western diet consumption, and obesity.\(^11\) Such rise by itself imposes a substantial psychosocial and economic impact on patients and relatives which also leads to the increase of the global burden from skin disease. Interestingly, more recent studies have shown a high exposure to allergens in tropical regions.\(^12\) In fact, a cross-sectional population-based study performed in 6 Colombian cities during 2009 and 2010 has shown a prevalence of atopic eczema of 14% (95% CI: 12.5–15.3%).\(^13\)

Management of AD not only requires pharmacological treatments. It also involves the use of non-reimbursed skin care products and the daily use of emollients in addition to transport or accommodation expenditures, and not-entirely reimbursed medical and psychological consultations.\(^14,15\) Therefore, the aim of this study was to describe important sociodemographic and clinical features and the economic burden of the disease on patients and their families in children and adult patients in Colombia in order to contribute to Latin America well-supported AD data. Such information is important not only to perform an in-depth characterization of this population and its needs, but it is also crucial in order to design more effective management strategies among Latin America communities.

PATIENTS AND METHODS

A cross-sectional, non-interventional observational study was performed, in which patients over 12 years of age with Colombian nationality, or foreigners residing for more than 15 years in the country, with a diagnosis of moderate to severe atopic dermatitis (defined by medical criteria), were included, with a convenience sampling approach. Patients with any mental disability were excluded. The recruitment period was 8 months (July 2019 to February 2020). Patients attended the dermatological consultation of private practice offices, health provider institutions, and hospitals from 6 different Colombian regions: North-East (Main city: Bucaramanga); North-West (Main city, coast: Barranquilla); Central area (Main cities: Bogota, Medellin, Armenia); South-West (Main city: Cali). Informed consent was obtained from all
adult patients and a signed consent form was obtained from all children and their parents or guardians. This study was approved by the Ethics and Investigation Committee of the IPS Universitaria as stated in Act # 134 of May 29, 2019.

All the researchers were previously trained in the use of the questionnaire. Data collection was performed in a stepwise approach: Step 1. The collection of economic features regarding the cost of illness and demographic data such as age, marital status, gender, education level, living place, health insurance, socioeconomic classification, and social security type. Step 2. A complete physical examination was performed by a dermatologist from which the clinically defined findings and diagnoses were recorded. For AD diagnosis, we used the diagnostic criteria of Hanifin and Rajka.\textsuperscript{16} Data related to disease distribution, disease severity (through the BSA: Body surface area; EASI: Eczema Area and Severity Index; SCORAD: Scoring Atopic Dermatitis), Fitzpatrick's skin phototypes, personal and familiar history of allergic diseases, previous treatments, and personal history of comorbidities, were also gathered. Food allergy information was taken from patient's history but it had to be diagnosed by the treating physician. The percentage of BSA involved was categorized as clear (0%), mild (>0.1 to <16%), moderate (16 to <40%), and severe (40–100%), as previously described.\textsuperscript{17} For EASI scoring (range: 0–72), erythema, excoriation, swelling and lichenification on the face/neck, upper and lower extremities and trunk were evaluated. The EASI strata were classified as follows: 0 = clear; 0.1–1 = almost clear; 1.1–7 = mild; 7.1–21 = moderate; 21.1–50 = severe; 50.1–72 = very severe.\textsuperscript{18} For SCORAD scoring (range: 0–103), 8 body areas were evaluated for erythema, excoriation, swelling, oozing/crusting, lichenification, and dryness in addition to pruritus and sleeplessness and the extent of the disease was calculated using the "rule of nines". The SCORAD strata were classified according to its scoring as follows: clear-mild 0–28.9, moderate 29–48.9, severe 49–103.\textsuperscript{19}

The patients' social security classification was defined according to the Colombian general social security health system, which operates in 2 main affiliation regimens: the contributory scheme (employees, independent workers) and the subsidized regime (lower income people). There is also a special regime which includes the military force, the police, all schoolteachers, and the Colombian national petroleum company (Ecopetrol).

Socioeconomic classification was performed through a surrogated marker for individual or family income according to the National Administrative Department of Statistics (DANE),\textsuperscript{20} which has been based on public services payment related to housing type and urban or rural environment. Such classification has been stratified as: Stratum 1: Low-Low; Stratum 2: Low; Stratum 3: Medium-Low; Stratum 4: Medium; Stratum 5: Medium-High; Stratum 6: High.\textsuperscript{20}

The cost of illness was determined according to the value of the resources expended by the patients as a result of their health disease. The exploration of economic expenses was done with both parents (when applicable) as in Colombia it is not unusual to find that the mother is the sole head of the household.

Income and illness investment were asked on a monthly base, and the costs related to treatment or in clothes, syndets, gloves, etc, were based on last year expenditures. All these data were included in the analysis.

**Statistical analysis**

A univariate analysis was performed to describe variables' frequency. For continuous quantitative variables that fulfilled the assumption of normality (Kolmogorov Smirnov), the mean was used as a measure of central tendency and the standard deviation as a measure of dispersion. For those quantitative variables whose distribution was not normal, the median and the minimum and maximum values were used for the presentation of the data. Absolute and relative frequencies and percentages were used for qualitative variables. A Spearman correlation test and a Chi-square test of independence were performed to compare BSA with EASI, and SCORAD and to compare EASI with SCORAD scores and severity strata, respectively. Bivariate analysis was performed by the Student’s t-test, one-way ANOVA, Chi-square, or U of Mann Whitney, as appropriate. The significance level was specified at 0.05 for all tests. For data processing, the SPSS (Statistical Package for Social Sciences) version 27, was used.
RESULTS

A total of 212 patients were included in this study. The mean age of participants was 28.5 years-old (range: 12-76 years). The main sociodemographic characteristics are presented in Table 1, where it should be noted that the population was made up mainly by females (52.8%), between 12 and 76 years old, with skin phototypes from II to IV (96.7%). The predominant marital status was being single (70.3%), and 68.9% of patients reported having a technical or professional degree. With regard to health insurance, the majority of patients (84%) belonged to the contributory regime. Regarding the economic characterization, 29.9% of the patients belonged to the medium-low stratum, 22% to the low stratum, 20.1% to the medium stratum, 15.9% to the medium-high stratum, 11.2% to the highest stratum and 0.9% to the low-low stratum. Gender was not associated with disease severity categories (measured either with EASI or SCORAD) \( (p = 0.09 \text{ and } p = 0.43, \text{ respectively; Chi}^2 \text{ Test of Independence}) \).

Regarding the clinical aspects and criteria for diagnosis shown in Table 2, disease distribution was mainly flexural (19.6%), combined with either eyelid dermatitis (11.7%), hand eczema (5.1%) or cheilitis (5.1%). In addition, early age start, Denni-Morgan fold and infections tendency were all more frequent in adolescents compared to adults. \( (p = 0.010 \text{ and } p = 0.013, \text{ respectively; Chi-Square test}) \).

Mean scores of BSA, EASI, and SCORAD involvement were 32.6, 13.7, and 42.4, respectively. Body-surface area, EASI, and SCORAD absolute scores were correlated with each other (All comparisons: \( \text{Rho}>0.7; p = 0.00, \text{ Spearman correlation test} \)) when BSA was compared with EASI, with SCORAD and when EASI was compared with SCORAD.

Mild, moderate and severe BSA scores were found in 29.7%, 35.4%, and 32.55% of patients, respectively. According to EASI scores, 33%, 39.6%, and 21.7% of the patients had mild, moderate or severe disease. Similarly, clear-mild, moderate and severe disease according to SCORAD were found in 24.5%, 36.8%, and 38.7% of the population.

When BSA strata were compared to EASI and to SCORAD, there was a statistical significant dependence of severity levels \( (p = 0.00 \text{ and } p = 0.00, \text{ respectively; Chi}^2 \text{ Test}) \).

With regard to the clinical and lifestyle aspects shown in Table 3, the median age of diagnosis of AD was 10 years old, being the diagnosis of AD made by a dermatologist in more than half of the cases (55.7%). About half of the patients reported alcohol consumption (48.1%), while smoking was found in less than 1 in every 10 patients (7.5%). The most common comorbidities were chronic rhinitis (68.9%), sleep disturbances (48.6%), asthma (39.6%), anxiety (20.7%), and depression (16.5%).

Comorbidities, previous treatments and economic features are depicted in Tables 4-6, respectively. Economic dependence, socioeconomic strata and

| Variable | n = 212 |
|----------|---------|
| Sex female, n (%) | 112 (52.8) |
| Age, years, mean (SD) | |
| 12-18 years | 53 (25) |
| >18 years | 159 (75) |
| Skin Phototype, n (%) | |
| II | 32 (15.1) |
| III | 116 (54.7) |
| IV | 57 (26.9) |
| V | 7 (3.3) |
| Marital status, n (%) | |
| Single | 149 (70.3) |
| Married | 45 (21.2) |
| Living common-law | 13 (6.1) |
| Divorced | 5 (2.4) |
| Highest educational level completed\(^a\), n (%) | |
| Elementary School | 7 (3.3) |
| Middle/High School | 59 (27.8) |
| Technician | 29 (13.7) |
| College | 78 (36.8) |
| Postgraduate | 39 (18.4) |
| Social security classification\(^b\), n (%) | |
| Contributory | 178 (84) |
| Subsidized | 32 (15.1) |
| Special regimen | 9 (4.2) |

Table 1. Sociodemographic characteristics of Colombian atopic dermatitis patients \( a. \text{ Referred by the patient}. \text{ b. Colombian general social security health system.} \)
monthly income were all associated with age strata (p = 0.00, 0.00, 0.001, respectively; Chi² Test), but no significant dependence was found with monthly investment in the disease (p = 0.08; Chi² Test). In addition, neither socioeconomic strata, economic dependence monthly income nor monthly disease investment were associated with disease severity (measured either with EASI or SCORAD) (All results p > 0.005; Chi² Test).

In addition, another relevant finding was that 37% of adult patients sought alternative medicine as other therapy option.

Finally, almost 40% of the patients had work or school absenteeism, mostly for 1-4 days (46 patients out of 212) followed by 5-8 days (15 patients out of 212) and less frequently for more than 9 days in the last 6 months.
DISCUSSION

The current study demonstrated major economic and health status impairments in a representative population of adolescent and adult patients with atopic dermatitis in Colombia. We characterized these patients with regards to socio-demographic variables, habits, and comorbidities,

| Variable | n = 212 | <18 years old n = 47 | >18 years old n = 165 |
|----------|---------|----------------------|----------------------|
| Age at diagnosis, median | 10 | 15 | 29 |
| Specialist or physician who had made the diagnosis, n (%) | | | |
| Dermatologist | 118 (55.7) | 21 (44.7) | 97 (58.8) |
| General physician | 37 (17.5) | 12 (25.5) | 25 (15.1) |
| Pediatrician | 33 (15.6) | 8 (17.0) | 25 (15.1) |
| Allergologist | 17 (8) | 6 (12.8) | 11 (6.7) |
| Other | 7 (3.3) | 0 (0.0) | 7 (4.2) |
| Habits, n (%) | | | |
| Alcohol | 102 (48.1) | 3 (6.4) | 99 (60) |
| Smoker | 16 (7.5) | 0 (0) | 16 (9.7) |
| Psychoactive substances | 6 (2.8) | 0 (0) | 6 (3.6) |
| History of psychiatric symptomsa, n (%) | | | |
| Anxiety | 44 (20.7) | 12 (25.5) | 32 (19.4) |
| Depression | 35 (16.5) | 7 (14.9) | 28 (16.7) |
| Attention deficit | 19 (9.0) | 4 (8.5) | 15 (9.1) |
| Sleep disturbancesa, n (%) | 103 (48.6) | 21 (44.7) | 82 (49.7) |
| Disease severity, mean (SDb) | | | |
| SCORAD | 42.4 (19.4) | 45.36 (20.3) | 41.57 (19.2) |
| EASI | 13.7 (11.8) | 14.26 (12.5) | 13.57 (11.6) |
| BSA | 32.5 (25.0) | 33.33 (24.8) | 32.42 (25.2) |

Table 3. Clinical aspects of Colombian adolescent and adult atopic dermatitis patients a. Referred by the patient. b. SD: standard deviation; SCORAD: scoring atopic dermatitis; EASI: eczema area and severity index; BSA: body surface area.

| Variable | n = 212 | <18 years old n = 47 | >18 years old n = 165 |
|----------|---------|----------------------|----------------------|
| Atopic Comorbidities, n (%) | | | |
| Allergic rhinitis | 146 (68.9) | 37 (90.2) | 109 |
| Asthma | 61 (28.8) | 12 (25.5) | 49 (29.7) |
| Food allergy | 69 (32.5) | 12 (25.5) | 57 (34.5) |
| Allergic conjunctivitis | 63 (29.7) | 11 (23.4) | 52 (31.5) |
| Metabolic Comorbidities, n (%) | | | |
| Thyroid disease | 8 (3.8) | 0 (0.0) | 8 (5) |
| Arterial hypertension | 8 (3.8) | 0 (0.0) | 8 (5) |
| Obesity | 5 (2.4) | 0 (0.0) | 5 (3) |
| Diabetes | 4 (1.9) | 0 (0.0) | 4 (2.4) |
| Dyslipidemia | 1 (0.5) | 0 (0.0) | 1 (0.6) |
| Other Comorbidities, n (%) | | | |
| Peptic ulcer | 5 (2.4) | 1 (2.1) | 4 (2.4) |
| COPDa | 1 (0.5) | 0 (0.0) | 1 (0.6) |
| OSA | 1 (0.5) | 0 (0.0) | 1 (0.6) |

Table 4. Comorbidities in Colombian adolescent and adult atopic dermatitis patients a. COPD: chronic obstructive pulmonary disease; OSA: Obstructive sleep apnea.
### Table 5. Treatment received in Colombian adolescent and adult atopic dermatitis patients

| Variable, n (%)                        | Total n = 212 | <18 years old n = 47 | >18 years old n = 165 |
|---------------------------------------|---------------|----------------------|----------------------|
| **Topical treatments, n (%)**         |               |                      |                      |
| Moisturizers                          | 209 (98.6)    | 47 (100)             | 162 (98.2)           |
| Topical corticosteroids               | 206 (97.2)    | 46 (97.9)            | 160 (96.7)           |
| Topical tacrolimus                    | 126 (59.4)    | 20 (42.5)            | 106 (64.2)           |
| **Systemic treatments, n (%)**        |               |                      |                      |
| Oral antihistamines                   | 183 (86.3)    | 41 (87.2)            | 142 (86)             |
| Systemic steroids                     | 133 (62.7)    | 23 (48.9)            | 110 (66.6)           |
| Phototherapy                          | 131 (61.8)    | 28 (59.5)            | 103 (62.4)           |
| Azathioprine                          | 60 (28.3)     | 7 (14.9)             | 53 (32.1)            |
| Cyclosporine                          | 47 (22.2)     | 6 (12.7)             | 41 (25)              |
| Methotrexate                          | 36 (17.0)     | 8 (17)               | 28 (17)              |
| Mycophenolate mofetil                 | 8 (3.8)       | 2 (4.2)              | 6 (3.6)              |
| **Biologic therapy, n (%)**           |               |                      |                      |
| Dupilumab                             | 14 (6.6)      | 0 (0.0)              | 14 (8.5)             |
| Omalizumab                            | 12 (5.7)      | 3 (6.3)              | 9 (5.5)              |

### Table 6. Economic aspects in atopic dermatitis patients in Colombia by age

| Variable, n (%)                        | Total n = 212 | 12-<18 years n = 53 | 18-65 years n = 155 | >65 years n = 4 |
|---------------------------------------|---------------|---------------------|---------------------|-----------------|
| **Economic dependence**               |               |                     |                     |                 |
| Yes                                   | 128 (59.8)    | 55 (100)            | 72 (46.6)           | 1 (25)          |
| No                                    | 86 (40.2)     | 0 (0)               | 83 (53.5)           | 3 (75)          |
| **Monthly income, CCMMW** a           |               |                     |                     |                 |
| No income                             | 91             | 44                  | 47                  | 0               |
| 1-50 CCMMW                            | 15             | 1                   | 14                  | 0               |
| 1-2 CCMMW                             | 34             | 5                   | 28                  | 1               |
| 3-4 CCMMW                             | 34             | 3                   | 31                  | 0               |
| 5-6 CCMMW                             | 16             | 0                   | 16                  | 0               |
| 7-10 CCMMW                            | 10             | 0                   | 8                   | 2               |
| 10-15 CCMMW                           | 8              | 1                   | 7                   | 0               |
| 16-20 CCMMW                           | 4              | 1                   | 3                   | 0               |
| >21 CCMMW                             | 2              | 0                   | 1                   | 1               |
| **Monthly investment in disease, USD** b |           |                     |                     |                 |
| 0-25 USD                              | 31             | 1                   | 29                  | 1               |
| 25-50 USD                             | 57             | 16                  | 40                  | 1               |
| 50-130 USD                            | 95             | 31                  | 63                  | 1               |
| 130-260 USD                           | 22             | 4                   | 17                  | 1               |
| >260 USD                              | 2              | 2                   | 0                   | 0               |
| Patient does not know                 | 7              | 1                   | 6                   | 0               |

---

*a. CCMMW: Current Colombian monthly minimum wage. One CCMMW is equivalent to approximately 224 US dollars. b. USD: US dollars.*
with alcohol consumption, and sleep disturbances (48.6%), as main concerns in this population. One of the first reports of AD in Colombia that is now more than 10 years-old focused on asthma and other allergic conditions in which AD symptoms were assessed through a well-performed school-based study with a multistage cluster sampling from Colombian private and public schools. Another Latin America study included at least 1000 children that were selected predominantly by a random sample of schools within the study area but such study also used self-respondent questionnaires of the International Study of Asthma and Allergies in Childhood (ISAAC) that assessed the symptoms of atopic eczema. A more recent study performed in an allergy referral center in Medellin, Colombia has described several risk factors for severe and persistent dermatitis and allergen sensitization in 94% of evaluated patients. Our study in comparison included adolescents (25%) and adult patients (75%) from 6 Colombian regions who were assessed in-person by experienced dermatologists what assured an objective characterization of the severity of the disease through the use of previously validated scales such as BSA, SCORAD, EASI, and at the same time, and a differential factor from other studies, it included an in-depth assessment of important sociodemographic characteristics as well as previous treatments and the cost of illness for patients and their families.

The mean age of interviewed patients was 28.5 years, a finding that is very relevant in this study, as this is the age at which an individual's productivity and labor could be more affected by the disease. In addition, the mean age of diagnosis of AD of our patients was at 10 years-old, a finding that contrasts with a previous report of patients from Medellin. In this respect, since the age of AD diagnosis was gathered through patient history, recall bias may have occurred, although we think it might be unlikely as the disease is such a stressful condition that most patients or their parents will probably remember when their life (or children’s life) changed with the onset of atopic dermatitis.

With regard to gender, we found a slight female preponderance, which has been also reported in other studies. This finding could be explained due to the predominance of adult patients, as several studies have found that AD is more frequent in boys during childhood, but it starts to be more frequent in females during adolescence and thereafter. However, it remains unclear why AD seems to be more frequent in women compared to men. Another interesting result regarding gender was its lack of association with AD disease severity, a finding that is similar to what has been reported in children and in adults with AD, although a higher prevalence of eczema has been found in women when compared with men.

A main concern in our study is the preponderance of being single and the important percentage of patients with anxiety and depression, findings that could suggest a negative impact of AD in formal relationships probably due to psychosocial stressors associated with the disease. Such impact has also been described in other populations in which never-married adults and higher rates of divorce and separation have been found.

Regarding the level of education, most of the included individuals finished school, high school, or college or had a technician or university degree. Although the level of education of the Colombian population tends to be lower, this finding could be explained by the inclusion of patients mostly with the contributive social security which in our country usually corresponds to people with a formal job, representing a better income.

Initial diagnosis of AD varies according to each country. Our study shows that more than half of the patients were diagnosed by a dermatologist (55.7%) followed by general practitioners (GP) (17.5%) and less frequent by pediatricians and allergologists with no differences between adolescents and adult patients. These findings contrast with other countries such as France, Italy, Germany, Spain, and the United Kingdom where patients are usually first diagnosed by their GPs. Although we do not have an explanation for such results we assume it has to do with the economic effort they make to consult a dermatologist in private practice or either with the level of dermatology training that other physicians receive during their medical career which is scarce in most medicine curricula in Colombia or with the lack of trained specialists in the
management of AD as has been reported in developing countries.  

Sleep deprivation, itch, and skin lesions localized mainly on visible areas can all cause social embarrassment and psychosocial alterations. We have confirmed that AD not only can have a detrimental effect on sleep, but it is also related with heavy alcohol intake, a finding that deserves further attention not only because it was more frequent than depression and anxiety (the 2 main psychiatric conditions usually reported), but also because it has been more frequently described only in recent years in patients with eczema and other inflammatory diseases such as psoriasis.  

In addition, our study also supports the already known link between AD and other allergic conditions such as asthma, rhinitis, and mite allergy in both, adolescents and adults. This is also consistent with several reports of the “allergic march”, in which AD has been shown to precede the appearance of other atopic conditions such as asthma, chronic rhinitis, and food allergy.  

Except for early age onset, recurrent infections and the Denni-Morgan infraorbital folds, there were no important differences in the majority of clinical variables evaluated in adolescent and adult patients, a result that contrasts with previous reports in which significant differences in atopic history, signs, and symptoms of <18 years in comparison to adult patients have been found. Such findings could be explained by the age-proximity of the majority of studied adolescents to adulthood which could in turn lead to phenotypical similarities.  

An accurate assessment of the severity and extent of AD is crucial not only to define its burden but also to evaluate the effects of treatment. In this study, we have assessed the severity of the disease through three of the main available instruments: BSA, EASI, and SCORAD. Interestingly, we have found a significant correlation between all scales when using absolute values and also when stratified scales were compared, findings that contrast with what has been reported previously. In addition, it is important to highlight that although at the time of evaluating the patients, the severity scales yielded scores corresponding to mild to moderate disease, it must be taken into account that almost all the patients were receiving either systemic, phototherapy, or biological treatment (Table 5), which influenced the finding of lower than expected scores when severity scales were applied. In this latter respect, we also confirm that the majority of adolescent and adult patients required the continuous use of emollients, topical corticosteroids, anti-histamines, and/or topical calcineurin inhibitors and that more than half of our adult patients have required systemic corticosteroids and other immunosuppressants such as cyclosporine or methotrexate, all of which put our patients at risk due to their already known side effects, particularly infection. These findings of the severity of the disease warrants strict monitoring of these patients as an elevated mortality has been reported among patients with the most severe or active types of eczema.  

As AD is well known for its chronicity and frequent exacerbations, not surprisingly, our study showed an important use of alternative medicine, a result that confirms the frustration and dissatisfaction of our patients with conventional treatment. All these contrast with the low use of a US Food and Drug Administration (FDA) approved biologic for AD such as dupilumab, a fact that can be explained by its recent launching into the Colombian market.  

With respect to income, the majority of our patients belonged to lower income strata (Stratum 4 or less), a finding that has been also described in the adult population of the United States. This finding is very important, given that in a previous Colombian multicenter study, a higher impact on QoL was found in the lower income strata among patients with different skin diseases. Other AD costs include physician visits, prescriptions, and hospital, emergency or non-prescription expenditures whereas indirect costs include impaired work productivity (presenteeism) and absenteeism from work. This was confirmed in our study in which not only 40.2% of patients have had work or school absenteeism, but also almost 60% of our population was economically dependent. In addition, 81% earned less than $896 US dollars (4 Current Colombian monthly minimum wage) and 59% invested around 6–30% of their monthly budget in their AD (US$300–3120) yearly, a result that exceeds the out-of-pocket expenses reported in a US community survey and also the costs on health-care of atopic eczema from a recent survey.
performed in all Europe. These findings are also reinforced by the fact that disease monthly investment was not different in adolescents vs adults. All these can be explained not only by our health system structure in which moisturizers and syndets are scarcely provided to patients and by the high cost of those products and of hypoallergenic or non-scented personal hygiene products. Also, 40% of the patients had work or school absenteeism during the last 6 months, most of them for 1–4 days, which is in line with the world literature regarding the indirect costs of the disease.

Not surprisingly, there were significant differences in economic dependence, socioeconomic strata, and monthly income according to age since it is expected that as people advance in age, their income and socioeconomic stratum improve and they become less economically dependent. In addition, none of these economic variables were influenced by the severity of AD which is in line with what has been reported in Europe, as patients suffering milder disease also incur very high extra costs to cover emollients, moisturizers, and not-reimbursed treatments.

The strength of this study relies not only on the in-person clinimetric evaluation of patients by experienced dermatologists but also on its target on patients recruited from different sources at the main cities in Colombia, and on its in-depth clinical and economical characterization of the disease, as previous worldwide AD data have been mainly collected through self-reported questionnaires sent by mail.

The limitation of our study was its probable selection bias due to the cross-sectional nature of the study and because patients with a history of moderate-severe disease may have participated at higher rates than those with mild AD. Additionally, and in relation to the aforementioned, we cannot know the reasons why other AD patients did not seek health care at the time we were developing the study.

CONCLUSION

This study highlights the significant disease burden associated with atopic dermatitis in a Latin American adolescent and adult population, suggesting the need for future research focused on AD effects on QoL, its risk factors, and therapeutic and prevention strategies.

Abbreviations
AD, Atopic dermatitis; BSA, Body surface area; EASI, Eczema Area and Severity Index; SCORAD, Scoring Atopic Dermatitis; DANE, National Administrative Department of Statistics (Colombia); ISAAC, International Study of Asthma and Allergies in Childhood; GP, General practitioners; FDA, Food and drugs administration; US, United States.

Ethical statement
All authors assure that in this study the following has been fulfilled:
1) This material is the authors’ own original work, which has not been previously published elsewhere.
2) The paper is not currently being considered for publication elsewhere.
3) The paper reflects the authors’ own research and analysis in a truthful and complete manner.
4) The paper properly credits the meaningful contributions of co-authors and co-researchers.
5) The results are appropriately placed in the context of prior and existing research.
6) All sources used are properly disclosed and cited.
7) All authors have been personally and actively involved in substantial work leading to the paper, and will take public responsibility for its content.

The project in which this study is framed (Title: “CARGA DE LA ENFERMEDAD Y CALIDAD DE VIDA DE PACIENTES ADULTOS Y ADOLESCENTES CON ECCEMA ATÓPICO: CARACTERIZACIÓN CLÍNICA Y SOCIODEMOGRÁFICA”) and its informed consent were both approved by the Ethics and Investigation Committee of the IPS Universitaria as stated in Act # 134 of May 29, 2019.

Authors contributions
Gloria Sanclemente: Conception and design of the study, methodology, acquisition of data, original and draft preparation, analysis and interpretation of data, writing-reviewing and editing of the manuscript, final approval of the submitted version. Natalia Hernandez: Conceptualization, acquisition of data, writing-original draft preparation. Daniela Chaparro: Conceptualization, statistical analysis, writing-original draft preparation, final approval of the submitted version. Liliana Tamayo: Acquisition of data, writing-original draft preparation, final approval of the submitted version. Angela Lopez: Acquisition of data, writing-original draft preparation, final approval of the submitted version.

Funding
This study was sponsored by the Asociación Colombiana de Dermatología y Cirugía Dermatológica (Asoccerma).

Authors’ consent for publication
All authors have consented to publication of the study.
Availability of data and materials
The data that support the findings of this study are available by request from the corresponding author. The data are not publicly available due to ethics committee/informed consent restrictions regarding the use of data from a third party, and due to participants’ privacy issues.

Declaration of competing interest
This study was sponsored by the Asociación Colombiana de Dermatología y Cirugía Dermatológica (Asocolderma) through a SanoFii Laboratories grant. However, this pharmaceutical laboratory has not participated in any workshop related to the study and has not being involved in the analysis or design and development of the study.

Acknowledgements
We thank all the patients for their willingness to participate. We are also grateful to Lina Marcela Barrera for her help in the logistic coordination of the study, and her assistance in the database design and data entry. We are grateful to the Asociación Colombiana de Dermatología y Cirugía Dermatológica (Asocolderma) for the sponsoring of this study and for its administrative support.

Author details
aGroup of Investigative Dermatology (GRID), University of Antioquia, Medellín, Colombia. bDermatosoluciones SAS, Calle 90 # 19A 49 Cons 501, Bogotá, Colombia. cPontificia Universidad Javeriana, Bogotá, Colombia. dUniversidad Pontificia Bolivariana, Medellín, Colombia. eIPS Fototerapia Bojanini y López SAS, Bogotá, Colombia.

REFERENCES
1. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, Group IPTS. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124:1251-1258.
2. Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin. 2017;35:283-289.
3. Chamlin SL, Chen MM. Quality-of-life outcomes and measurement in childhood atopic dermatitis. Immunol Allergy Clin North Am. 2010;30:281-288.
4. Kage P, Simon JC, Treudler R. Atopic dermatitis and psychosocial comorbidities. J Dtsch Dermatol Ges. 2020;18:93-102.
5. Reed B, Blaiss MS. The burden of atopic dermatitis. Allergy Asthma Proc. 2018;39:406-410.
6. Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73:1284-1293.
7. Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32:1645-1651.
8. Kim DH, Li K, Seo SJ, et al. Quality of life and disease severity are correlated in patients with atopic dermatitis. J Korean Med Sci. 2012;27:1327-1332.
9. Hajar T, Simpson EL. The rise in atopic dermatitis in young children: what is the explanation? JAMA Netw Open. 2018;1, e184205.
10. Lopez Carrera YI, Al Hammadi A, Huang YH, Llamado LJ, Mahgoub E, Tallman AM. Epidemiology, diagnosis, and treatment of atopic dermatitis in the developing countries of Asia, Africa, Latin America, and the Middle East: a review. Dermatol Ther (Heidelb). 2019;9:685-705.
11. Kaufman BP, Guttmann-Yassky E, Alexis AF. Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment. Exp Dermatol. 2018;27:340-357.
12. Sánchez J, Toro Y, Cardona R. Clinical impact in the real life of guidelines recommendations for atopic dermatitis in a tropical population (TECCEMA cohort). Rev Alerg Mex. 2017;64:260-269.
13. Dennis RJ, Carballo L, García E, et al. Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study. BMC Pulm Med. 2012;12:1-9.
14. Ring J, Zink A, Arens BWM, et al. Atopic eczema: burden of disease and individual suffering - results from a large EU study in adults. J Eur Acad Dermatol Venereol. 2019;33:1331-1340.
15. Zink AGS, Arens B, Fink-Wagner A, et al. Out-of-pocket costs for individuals with atopic eczema: a cross-sectional study in nine European countries. Acta Derm Venereol. 2019;99:263-267.
16. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermato-Venereologica [Suppl](Stockh). 1980;92:44-47.
17. Silverberg JI, Tallman AM, Ports WC, Gerber RA, Tan H, Zielinski MA. Evaluating the efficacy of crisaborole using the atopic dermatitis severity index and percentage of affected body surface area. Acta Derm Venereol. 2020;100:adv00170.
18. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172:1353-1357.
19. Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for eczema area and severity index (EASI), modified EASI, scoring atopic dermatitis (SCORAD), objective SCORAD, atopic dermatitis severity index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177:1316-1321.
20. Dana, Ministerio de Hacienda y Credito Publico. Evaluación de la estratificación socioeconómica como instrumento de clasificación de los usuarios y herramienta de asignación de subsidios y contribuciones a los servicios públicos domiciliarios. http://www.dane.gov.co/files/geoesestadistica/Evaluacion_Estratificacion.pdf. Accessed 23 Apr 2021.
21. Solé D, Mallol J, Wandalsen GF, Aguirre V, Group LAIPS. Prevalence of symptoms of eczema in Latin America: results of the international study of asthma and allergies in childhood (ISAAC) phase 3. J Investig Allergol Clin Immunol. 2010;20:311-323.
22. Sánchez J, Sánchez A, Cardona R. Particular characteristics of atopic eczema in tropical environments. The tropical environment control for chronic eczema and molecular assessment (TECCEMA) cohort study. *An Bras Dermatol*. 2017;92:177–183.

23. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. *J Am Acad Dermatol*. May 1996;34(5 Pt 1):760–764.

24. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. *J Allergy Clin Immunol*. 2013;132:1132–1138.

25. Janković S, Ražnatović-Durović M, Čirković A, Janković J. Does gender influence quality of life in children with atopic dermatitis? *Scr Med*. 2019;50:19–24.

26. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. *J Invest Dermatol*. 2019;139:583–590.

27. Hua T, Silverberg JI. Atopic dermatitis in US adults: epidemiology, association with marital status, and atopy. *Ann Allergy Asthma Immunol*. 2018;121:622–624.

28. Lee JS, Kim JM, Seok J, Kim BJ. Correlation between socioeconomic status and atopic dermatitis in Korean adults: the Korea national health and nutrition examination survey (2007-2014). *J Eur Acad Dermatol Venereol*. 2017;31:1509–1515.

29. de Carlo G, Romagosa S, Palkonen S. Atopic Eczema. Itching for Life. European Federation of Allergy and Airways Diseases Patients’ Associations. http://www.efanet.org/images/2018/EN_itching_for_life_Quality_of_Life_and_costs_for_people_with_severe_atopiceczema_in_Europe.pdf. Accessed 23 Nov 2020.

30. Al-Jefri K, Newbury-Birch D, Muirhead CR, et al. High prevalence of alcohol use disorders in patients with inflammatory skin diseases. *Br J Dermatol*. 2017;177:837–844.

31. Illi S, von Mutius E, Lau S, et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. *J Allergy Clin Immunol*. 2004;113:925–931.

32. Shaker M. New insights into the allergic march. *Curr Opin Pediatr*. 2014;26:516–520.

33. Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. *ISRN Allergy*. 2014:1–7.

34. Son JH, Chung BY, Kim HO, Park CW. Clinical features of atopic dermatitis in adults are different according to onset. *J Korean Med Sci*. 2017;32:1360–1366.

35. Silverberg JI, Vakharia PP, Chopra R, et al. Phenotypical differences of childhood- and adult-onset atopic dermatitis. *J Allergy Clin Immunol Pract*. 2018;6:1306–1312.

36. Chopra R, Vakharia PP, Sacotte R, et al. Relationship between EASI and SCORAD severity assessments for atopic dermatitis. *J Allergy Clin Immunol*. 2017;140:1708–1710.

37. Silverwood RJ, Mansfield KE, Mulick A, et al. Atopic eczema in adulthood and mortality: UK population-based cohort study, 1998-2016. *J Allergy Clin Immunol*. 2021;147:1753–1763.

38. Silverberg JI, Reed ML, Group EPaIW. A population-based survey of eczema prevalence in the United States. *Dermatitis*. 2007;18:82–91.

39. Sanclemente G, Burgos C, Nova J, et al. The impact of skin diseases on quality of life: a multicenter study. *Actas Dermosifiliográficas (English Edition)*. 2017;108:244–252.

40. Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the national eczema association. *J Invest Dermatol*. 2017;137:26–30.

41. Anderson RT, Rajagopalan R. Effects of allergic dermatosis on health-related quality of life. *Curr Allergy Asthma Rep*. 2001;1:309–315.

42. Zuberbier T, Orlow SJ, Paller AS, et al. Patient perspectives on the management of atopic dermatitis. *J Allergy Clin Immunol*. 2006;118:226–232.